Long-term follow-up of venetoclax in CLL

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term follow-up fo clinical trials versus real-world data concerning the use of venetoclax in patients with chronic lymphocytic leukemia (CLL), including long-term safety and efficacy data, as well as clinical factors that may predict response such as minimal residual disease and genetic aberrations. Dr Davids also discusses real-world data of venetoclax in CLL presented at ESH CLL this year and highlights similarities between real-world responses and responses seen within clinical trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).